HCW Biologics (HCWB) vs Lakewood-Amedex Biotherapeutics (LABT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
HCW Biologics is the larger company by market cap ($2.4 million vs $2.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HCWB | LABT |
|---|---|---|
| Share price | $0.7491 | $0.2449 |
| Market cap | $2.35M | $2.19M |
| 1-day change | +1.90% | +15.03% |
| EPS (TTM) | $-9.09 | $-5.57 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $54.23K | — |
| Revenue growth (YoY) | -97.89% | — |
| Net income (latest FY) | $-7.96M | — |
| Gross margin | 20.00% | — |
| Operating margin | -24270.74% | — |
| Net margin | -14677.14% | — |
| 52-week high | $23.94 | $98.20 |
| 52-week low | $0.70 | $0.17 |
| Distance from 52-week high | -96.87% | -99.75% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +6307.69% | +4799.96% |
| Average volume | 379.38K | 16.14M |
| Shares outstanding | 3.14M | 8.95M |
| Employees | 35 | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About HCW Biologics
HCWB stock →HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in clinical trial in patients with alopecia areata diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 35 employees
About Lakewood-Amedex Biotherapeutics
LABT stock →Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
HCWB vs LABT FAQ
Which is bigger, HCW Biologics or Lakewood-Amedex Biotherapeutics?
HCW Biologics (HCWB) is larger, with a market capitalization of $2.35M compared with $2.19M for Lakewood-Amedex Biotherapeutics (LABT).
Are HCW Biologics and Lakewood-Amedex Biotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.